Nivolumab-Induced Periaortitis Demonstrated by FDG PET/CT. (November 2020)

• Record Type: Journal Article
• Authors: Hotta, Masatoshi; Naka, Go; Minamimoto, Ryogo; Takeda, Yuichiro; Hojo, Masayuki
• Is Part Of: Clinical nuclear medicine. Volume 45:Number 11(2020)
• Publication Date: 2020-11
• Subjects: immune check point inhibitor -- immune-related adverse event -- nivolumab -- periaortitis -- PET/CT -- vasculitis; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000003215
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: A 66-year-old man with a history of non–small cell lung cancer treated with nivolumab underwent contrast-enhanced CT and FDG PET/CT. No recurrence was demonstrated; however, soft-tissue thickening that showed delayed contrast enhancement and FDG uptake was detected around an abdominal aortic aneurysm. After discontinuation of nivolumab, the periaortic lesion disappeared within 2 months, indicating nivolumab-induced periaortitis. Immune checkpoint inhibitors such as nivolumab can cause vasculitis and periaortitis, a potentially fatal condition, as immune-related adverse events. The underlying aortic aneurysm may have contributed to genesis of periaortitis. FDG PET/CT can be useful for detecting periaortitis and excluding other forms of vasculitis.